Anesiva cuts jobs and preclinical work
This article was originally published in Scrip
Executive Summary
Anesivahas shelved its preclinical operations and cut around 20% of its workforce as it begins to target pain management. The US company will now concentrate on commercial and late-stage product development as well as in-licensing opportunities.